311 related articles for article (PubMed ID: 12682635)
1. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.
Derksen PW; de Gorter DJ; Meijer HP; Bende RJ; van Dijk M; Lokhorst HM; Bloem AC; Spaargaren M; Pals ST
Leukemia; 2003 Apr; 17(4):764-74. PubMed ID: 12682635
[TBL] [Abstract][Full Text] [Related]
2. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma.
Derksen PW; Keehnen RM; Evers LM; van Oers MH; Spaargaren M; Pals ST
Blood; 2002 Feb; 99(4):1405-10. PubMed ID: 11830493
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
Dong G; Chen Z; Li ZY; Yeh NT; Bancroft CC; Van Waes C
Cancer Res; 2001 Aug; 61(15):5911-8. PubMed ID: 11479233
[TBL] [Abstract][Full Text] [Related]
4. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways.
Bowers DC; Fan S; Walter KA; Abounader R; Williams JA; Rosen EM; Laterra J
Cancer Res; 2000 Aug; 60(15):4277-83. PubMed ID: 10945642
[TBL] [Abstract][Full Text] [Related]
5. Cooperative effect of hepatocyte growth factor and fibronectin in anchorage-independent survival of mammary carcinoma cells: requirement for phosphatidylinositol 3-kinase activity.
Qiao H; Saulnier R; Patryzkat A; Rahimi N; Raptis L; Rossiter J; Tremblay E; Elliott B
Cell Growth Differ; 2000 Feb; 11(2):123-33. PubMed ID: 10714768
[TBL] [Abstract][Full Text] [Related]
6. Mitogenic synergy through multilevel convergence of hepatocyte growth factor and interleukin-4 signaling pathways.
Day RM; Soon L; Breckenridge D; Bridges B; Patel BK; Wang LM; Corey SJ; Bottaro DP
Oncogene; 2002 Mar; 21(14):2201-11. PubMed ID: 11948403
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of the phosphoinositide 3-kinase and MAP kinase pathways by hepatocyte growth factor vs. insulin-like growth factor-I in myogenic cells.
Halevy O; Cantley LC
Exp Cell Res; 2004 Jul; 297(1):224-34. PubMed ID: 15194438
[TBL] [Abstract][Full Text] [Related]
8. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma.
Tjin EP; Groen RW; Vogelzang I; Derksen PW; Klok MD; Meijer HP; van Eeden S; Pals ST; Spaargaren M
Blood; 2006 Jan; 107(2):760-8. PubMed ID: 16189274
[TBL] [Abstract][Full Text] [Related]
9. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy.
Jankowski K; Kucia M; Wysoczynski M; Reca R; Zhao D; Trzyna E; Trent J; Peiper S; Zembala M; Ratajczak J; Houghton P; Janowska-Wieczorek A; Ratajczak MZ
Cancer Res; 2003 Nov; 63(22):7926-35. PubMed ID: 14633723
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+).
Weimar IS; Miranda N; Muller EJ; Hekman A; Kerst JM; de Gast GC; Gerritsen WR
Exp Hematol; 1998 Aug; 26(9):885-94. PubMed ID: 9694510
[TBL] [Abstract][Full Text] [Related]
11. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma.
Coltella N; Manara MC; Cerisano V; Trusolino L; Di Renzo MF; Scotlandi K; Ferracini R
FASEB J; 2003 Jun; 17(9):1162-4. PubMed ID: 12709413
[TBL] [Abstract][Full Text] [Related]
12. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
Hov H; Holt RU; Rø TB; Fagerli UM; Hjorth-Hansen H; Baykov V; Christensen JG; Waage A; Sundan A; Børset M
Clin Cancer Res; 2004 Oct; 10(19):6686-94. PubMed ID: 15475459
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte growth factor promotes migration of human myeloma cells.
Holt RU; Fagerli UM; Baykov V; Rø TB; Hov H; Waage A; Sundan A; Børset M
Haematologica; 2008 Apr; 93(4):619-22. PubMed ID: 18326526
[TBL] [Abstract][Full Text] [Related]
14. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte growth factor promotes cell proliferation and inhibits progesterone secretion via PKA and MAPK pathways in a human granulosa cell line.
Taniguchi F; Harada T; Deura I; Iwabe T; Tsukihara S; Terakawa N
Mol Reprod Dev; 2004 Jul; 68(3):335-44. PubMed ID: 15112327
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase C-betaII represses hepatocyte growth factor-induced invasion by preventing the association of adapter protein Gab1 and phosphatidylinositol 3-kinase in melanoma cells.
Oka M; Kikkawa U; Nishigori C
J Invest Dermatol; 2008 Jan; 128(1):188-95. PubMed ID: 17625596
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth.
Cai W; Rook SL; Jiang ZY; Takahara N; Aiello LP
Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1885-93. PubMed ID: 10845613
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway.
Paumelle R; Tulasne D; Kherrouche Z; Plaza S; Leroy C; Reveneau S; Vandenbunder B; Fafeur V
Oncogene; 2002 Apr; 21(15):2309-19. PubMed ID: 11948414
[TBL] [Abstract][Full Text] [Related]
19. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA
Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369
[TBL] [Abstract][Full Text] [Related]
20. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
Slørdahl TS; Denayer T; Moen SH; Standal T; Børset M; Ververken C; Rø TB
Eur J Haematol; 2013 Nov; 91(5):399-410. PubMed ID: 23952536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]